Matching the dose to the disease: Successful treatment of recalcitrant pyoderma gangrenosum using high-dose secukinumab

Dermatol Ther. 2022 Sep;35(9):e15669. doi: 10.1111/dth.15669. Epub 2022 Jul 5.

Authors

James Coe¹, Shobha Kudva¹, Kave Shams^{1

2}

Affiliations

¹ Leeds Centre for Dermatology, Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
² National Institute for Health Research, Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), Leeds, UK.

PMID: 35762275
DOI: 10.1111/dth.15669

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Pyoderma Gangrenosum* / diagnosis
Pyoderma Gangrenosum* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
secukinumab